Three biotech IPOs were added in the last few months, bringing the total since last August to 23 IPOs. Genmark Diagnostics (US), CorMedix (US), and Novagali (France) each raised under $30M, which is under the median amount raised for all 23 biotech IPOs - globally ($39M) and in the US ($79M) . The post IPO performance continues to be weak, with the median stock performance down over 20%. One of the few stocks in positive territory is Talecris Biotherapeutics, which is now being acquired by Spanish healthcare company Grifols for just over $3B.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200
© BIO 2020 All Rights Reserved